- Home
- TXMD vs JAGX Comparison
TXMD vs JAGX Comparison
Compare TXMD & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- JAGX
- Stock Information
- Founded
- TXMD 2008
- JAGX 2013
- Country
- TXMD United States
- JAGX United States
- Employees
- TXMD N/A
- JAGX N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- JAGX Health Care
- Exchange
- TXMD Nasdaq
- JAGX Nasdaq
- Market Cap
- TXMD 12.8M
- JAGX 12.9M
- IPO Year
- TXMD N/A
- JAGX N/A
- Fundamental
- Price
- TXMD $1.30
- JAGX $0.86
- Analyst Decision
- TXMD
- JAGX
- Analyst Count
- TXMD 0
- JAGX 0
- Target Price
- TXMD N/A
- JAGX N/A
- AVG Volume (30 Days)
- TXMD 738.0K
- JAGX 311.0K
- Earning Date
- TXMD 03-28-2025
- JAGX 03-31-2025
- Dividend Yield
- TXMD N/A
- JAGX N/A
- EPS Growth
- TXMD N/A
- JAGX N/A
- EPS
- TXMD N/A
- JAGX N/A
- Revenue
- TXMD $1,596,000.00
- JAGX $10,480,000.00
- Revenue This Year
- TXMD $605.07
- JAGX $18.18
- Revenue Next Year
- TXMD $1.11
- JAGX $40.06
- P/E Ratio
- TXMD N/A
- JAGX N/A
- Revenue Growth
- TXMD N/A
- JAGX N/A
- 52 Week Low
- TXMD $0.70
- JAGX $0.78
- 52 Week High
- TXMD $2.75
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- TXMD 68.51
- JAGX 45.91
- Support Level
- TXMD $0.95
- JAGX $0.78
- Resistance Level
- TXMD $1.08
- JAGX $1.03
- Average True Range (ATR)
- TXMD 0.09
- JAGX 0.07
- MACD
- TXMD 0.02
- JAGX 0.01
- Stochastic Oscillator
- TXMD 49.30
- JAGX 30.44
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.